Trial reportJournal of the American Society of Nephrology : JASN2019
Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.
Trial report in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intensive Blood Pressure Treatment Goals: Evidence for Cardiovascular Protection From Observational Studies and Clinical Trials.American journal of hypertension · 2022Pooled it
- Plasma Biomarkers of Kidney Tubule Health during Ambulatory AKI and Kidney Function Recovery in SPRINT.Clinical journal of the American Society of Nephrology : CJASN · 2026Trial
- Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD: A Post Hoc Analysis of SPRINT and ACCORD-BP Trials.Journal of diabetes · 2025Trial
- Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Trial
- Trial
- Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Trial
- Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.Nephrology (Carlton, Vic.) · 2021Trial
- Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial.Journal of the American Society of Nephrology : JASN · 2020Trial
- Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants.American journal of nephrology · 2020Trial
- The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation.Journal of the American Society of Nephrology : JASN · 2024Article
- Revisiting resistant hypertension in kidney disease.Current opinion in nephrology and hypertension · 2024Review
- Changes in Natriuretic Peptide Levels and Subsequent Kidney Function Decline in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Observational
- Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Observational
- Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- Review
- Decline in the estimated glomerular filtration rate (eGFR) following metabolic control and its relationship with baseline eGFR in type 2 diabetes with microalbuminuria or macroalbuminuria.Diabetology international · 2022Article
- The roles of sodium and volume overload on hypertension in chronic kidney disease.Kidney research and clinical practice · 2021Article
- SPRINT Revisited: Updated Results and Implications.Hypertension (Dallas, Tex. : 1979) · 2021Review
- Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care.Circulation. Cardiovascular quality and outcomes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundThe Systolic BP Intervention Trial (SPRINT) found that intensive versus standard systolic BP control (targeting <120 or <140 mm Hg, respectively) reduced the risks of death and major cardiovascular events in persons with elevated cardiovascular disease risk. However, the intensive intervention was associated with an early decline in eGFR, and the clinical implications of this early decline are unclear.
methodsIn a
resultsAbout 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm (
conclusionsAlthough intensive systolic BP lowering resulted in greater early decline in eGFR, there was no evidence that the reduction in eGFR owing to intensive systolic BP lowering attenuated the beneficial effects of this intervention on cardiovascular events or all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.